1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit

Cancer Cell

Volumn 23, Issue 4, 2013, Pages 541-556

  Zhao, Wei ^a   Wang, Limin ^a   Han, Haibo ^a   Jin, Kemin ^a   Lin, Na ^b   Guo, Ting ^a   Chen, Yangde ^c   Cheng, Heping ^b   Lu, Fengmin ^d   Fang, Weigang ^d   Wang, Yu ^a   Xing, Baocai ^a   Zhang, Zhiqian ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b PEKING UNIVERSITY   (China)

^c SANOFI   (France)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL ALPHA2DELTA1; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM ION; CD133 ANTIGEN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; MICROSOMAL AMINOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1B50 1; TUMOR MARKER; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENICITY; CARCINOMA CELL; CELL DIFFERENTIATION; CELL INVASION; CELL RENEWAL; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SUBUNIT; TUMOR ENGRAFTMENT;

EID: 84876395186     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.02.025     Document Type: Article

References (38)

1. Alison M.R., Lim S.M., Nicholson L.J. Cancer stem cells: problems for therapy?. J. Pathol. 2011, 223:147-161.
2. Brooks P.C., Lin J.M., French D.L., Quigley J.P. Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis. J. Cell Biol. 1993, 122:1351-1359.
3. Chiba T., Kita K., Zheng Y.-W., Yokosuka O., Saisho H., Iwama A., Nakauchi H., Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
4. Chiba T., Miyagi S., Saraya A., Aoki R., Seki A., Morita Y., Yonemitsu Y., Yokosuka O., Taniguchi H., Nakauchi H., Iwama A. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 2008, 68:7742-7749.
5. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
6. Darwiche H., Petersen B.E. Biology of the adult hepatic progenitor cell: "ghosts in the machine" Prog. Mol. Biol. Transl. Sci. 2010, 97:229-249.
7. De Jongh K.S., Warner C., Catterall W.A. Subunits of purified calcium channels. Alpha 2 and delta are encoded by the same gene. J. Biol. Chem. 1990, 265:14738-14741.
8. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
9. Dolmetsch R.E., Lewis R.S., Goodnow C.C., Healy J.I. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 1997, 386:855-858.
10. Dolmetsch R.E., Xu K., Lewis R.S. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998, 392:933-936.
11. Dolmetsch R.E., Pajvani U., Fife K., Spotts J.M., Greenberg M.E. Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science 2001, 294:333-339.
12. Eroglu C., Allen N.J., Susman M.W., O'Rourke N.A., Park C.Y., Ozkan E., Chakraborty C., Mulinyawe S.B., Annis D.S., Huberman A.D., et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009, 139:380-392.
13. Ferreira-Martins J., Rondon-Clavo C., Tugal D., Korn J.A., Rizzi R., Padin-Iruegas M.E., Ottolenghi S., De Angelis A., Urbanek K., Ide-Iwata N., et al. Spontaneous calcium oscillations regulate human cardiac progenitor cell growth. Circ. Res. 2009, 105:764-774.
14. Haraguchi N., Ishii H., Mimori K., Tanaka F., Ohkuma M., Kim H.M., Akita H., Takiuchi D., Hatano H., Nagano H., et al. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 2010, 120:3326-3339.
15. Hoey T., Yen W.-C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.-K., Sato A., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
16. Hu Y., Smyth G.K. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 2009, 347:70-78.
17. Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., Mukeria A., Szeszenia-Dabrowska N., Lissowska J., Rudnai P., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
18. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., Guthridge M.A., Thomas D., Barry E.F., Boyd A., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
19. Kapur N., Mignery G.A., Banach K. Cell cycle-dependent calcium oscillations in mouse embryonic stem cells. Am. J. Physiol. Cell Physiol. 2007, 292:C1510-C1518.
20. Lee C.-H., Huang C.-S., Chen C.-S., Tu S.-H., Wang Y.-J., Chang Y.-J., Tam K.-W., Wei P.-L., Cheng T.-C., Chu J.-S., et al. Overexpression and activation of the α9-nicotinic receptor during tumorigenesis in human breast epithelial cells. J. Natl. Cancer Inst. 2010, 102:1322-1335.
21. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation. Cell Stem Cell 2011, 9:50-63.
22. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
23. Ma S., Tang K.H., Chan Y.P., Lee T.K., Kwan P.S., Castilho A., Ng I., Man K., Wong N., To K.F., et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707.
24. MacLeod R.J., Hayes M., Pacheco I. Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G403-G411.
25. Mishra L., Banker T., Murray J., Byers S., Thenappan A., He A.R., Shetty K., Johnson L., Reddy E.P. Liver stem cells and hepatocellular carcinoma. Hepatology 2009, 49:318-329.
26. Rappa G., Fodstad O., Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008, 26:3008-3017.
27. Rasmussen N., Ditzel H.J. Scanning the cell surface proteome of cancer cells and identification of metastasis-associated proteins using a subtractive immunization strategy. J. Proteome Res. 2009, 8:5048-5059.
28. Rosen J.M., Jordan C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324:1670-1673.
29. Sell S., Leffert H.L. Liver cancer stem cells. J. Clin. Oncol. 2008, 26:2800-2805.
30. Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
31. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
32. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
33. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
34. Vukcevic M., Zorzato F., Spagnoli G., Treves S. Frequent calcium oscillations lead to NFAT activation in human immature dendritic cells. J. Biol. Chem. 2010, 285:16003-16011.
35. Xu X.L., Xing B.C., Han H.B., Zhao W., Hu M.H., Xu Z.L., Li J.Y., Xie Y., Gu J., Wang Y., Zhang Z.Q. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis 2010, 31:167-174.
36. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.Y., Jia H., Ye Q., Qin L.X., Wauthier E., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136:1012-1024.
37. Yovchev M.I., Grozdanov P.N., Joseph B., Gupta S., Dabeva M.D. Novel hepatic progenitor cell surface markers in the adult rat liver. Hepatology 2007, 45:139-149.
38. Zhang M., Atkinson R.L., Rosen J.M. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2010, 107:3522-3527.